Evidence map›Paper›PMID 36553158›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Gradient-Boosting Algorithm for Microwave Breast Lesion Classification-SAFE Clinical Investigation.

Aleksandar Janjic, Ibrahim Akduman, Mehmet Cayoren, Onur Bugdayci, Mustafa Erkin Aribal

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aleksandar JanjicMitos Medical Technologies, ITU Ayazaga Ari Teknokent 2-B Block 2-2-E, 34469 Istanbul, Turkey.
Ibrahim AkdumanMitos Medical Technologies, ITU Ayazaga Ari Teknokent 2-B Block 2-2-E, 34469 Istanbul, Turkey.ORCID 0000-0002-5769-6032
Mehmet CayorenMitos Medical Technologies, ITU Ayazaga Ari Teknokent 2-B Block 2-2-E, 34469 Istanbul, Turkey.
Onur BugdayciDepartment of Radiology, School of Medicine, Marmara University, 34899 Istanbul, Turkey.ORCID 0000-0002-6011-2720
Mustafa Erkin AribalMitos Medical Technologies, ITU Ayazaga Ari Teknokent 2-B Block 2-2-E, 34469 Istanbul, Turkey.ORCID 0000-0002-5525-8696

Funding

Horizon 2020 764479Scientific and Technology Research Council of Turkey (TUBITAK) 120N388
6 · The paper itself

Abstract

(1) Background: Microwave breast imaging (MBI) is a promising breast-imaging technology that uses harmless electromagnetic waves to radiate the breast and assess its internal structure. It utilizes the difference in dielectric properties of healthy and cancerous tissue, as well as the dielectric difference between different cancerous tissue types to identify anomalies inside the breast and make further clinical predictions. In this study, we evaluate the capability of our upgraded MBI device to provide breast tissue pathology. (2) Methods: Only patients who were due to undergo biopsy were included in the study. A machine learning (ML) approach, namely Gradient Boosting, was used to understand information from the frequency spectrum, collected via SAFE, and provide breast tissue pathology. (3) Results: A total of 54 patients were involved in the study: 29 of them had benign and 25 had malignant findings. SAFE acquired 20 true-positive, 24 true-negative, 4 false-positive and 4 false-negative findings, achieving the sensitivity, specificity and accuracy of 80%, 83% and 81%, respectively. (4) Conclusions: The use of harmless tissue radiation indicates that SAFE can be used to provide the breast pathology of women of any age without safety restrictions. Results indicate that SAFE is capable of providing breast pathology at a high rate, encouraging further clinical investigations.

Indexed as

breast lesion classificationmachine learningmicrowave breast imaging (MBI)SAFE

Identifiers

PMID36553158
PMCPMC9777022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.